Search

Author/Creator Miyazaki, Y.

41. Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA. (May 2023)

Authors:
Okuda, R.; Ochi, Y.; Saiki, R.; Chonabayashi, K.; Hiramoto, N.; Sanada, M.; Handa, H.; Kasahara, S.; Sato, S.; Kanemura, N.; Kitano, T.; Watanabe, M.; Kern, W.; Creignou, M.; Shiraishi, Y.; Watanabe, M.; Usuki, K.; Imashuku, S.; Hellstrom-Lindberg, E.; Haferlach, T.
Journal:
Leukemia research
Issue:
Volume 128(2023)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

42. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: MYELOID NEOPLASMS WITH GERMLINE AND SOMATIC DDX41 MUTATIONS. (September 2021)

Authors:
Makishima, H.; Nannya, Y.; Momozawa, Y.; Gurnari, C.; Kulasekararaj, A.; Yoshizato, T.; Takeda, J.; Atsuta, Y.; Shiozawa, Y.; Iijima-Yamashita, Y.; Saiki, R.; Yoshida, K.; Shiraishi, Y.; Nagata, Y.; Onizuka, M.; Nakagawa, M.; Itonaga, H.; Kanda, Y.; Miyazaki, Y.; Sanada, M.
Journal:
Leukemia research
Issue:
Volume 108(2021)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

43. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE. (May 2023)

Authors:
Pfeilstöcker, M.; Tuechler, H.; Ades, L.; Cermak, J.; Chermat, F.; Della Porta, M.; Fenaux, P.; Garcia-Manero, G.; Germing, U.; Haase, D.; Kündgen, A.; Lübbert, M.; Magalhaes, S.; Malcovati, L.; Miyazaki, Y.; Sanz, G.; Santini, V.; Sekeres, M.; Walter, M.; Valent, P.
Journal:
Leukemia research
Issue:
Volume 128(2023)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

44. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES. (September 2021)

Authors:
Zeidan, A.M.; Garcia, J.; Fenaux, P.; Platzbecker, U.; Miyazaki, Y.; Xiao, Z.; Zhou, Y.; Naqvi, K.; Kye, S.; Manero, G. Garcia
Journal:
Leukemia research
Issue:
Volume 108(2021)Supplement
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗